A Phase 1-2 Study Of Combination Therapy With INCMGA00012 (Anti PD-1), INCAGN02385 (Anti LAG-3), And INCAGN02390 (Anti TIM-3) In Participants With Select Advanced Malignancies Read more
A Phase 1 Study Exploring The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of INCB099318 In Participants With Select Advanced Solid Tumors Read more
A Phase 1/2 First-In-Human Study Of BMS-986288 Alone And In Combination With Nivolumab In Advanced Malignant Tumors Read more
A Phase 1/2 Study Of BMS-986340 As Monotherapy And In Combination With Nivolumab In Participants With Advanced Solid Tumors Read more
Phase 1 Study Of BMS-986416 (TGF-B Inhibitor) Alone And In Combination With Nivolumab In Advanced Malignant Tumors. Read more
A Randomized Phase II/III Open-Label Study Of Ipilimumab And Nivolumab Versus Temozolomide In Patients With Actively Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma Read more
Treatment Of Actively Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) And Relapsed Favorable Histology Wilms Tumors (FHWT) Read more
A Phase 2, Open-Label Study Of Encorafenib + Binimetinib In Patients With BRAFV600E-Mutant Non-Small Cell Lung Cancer Read more
A Phase 1/2 Feasibility, Safety, And Activity Study Of PSCA-Specific Chimeric Antigen Receptor Engineered T Cells (BPX-601) In Subjects With Previously Treated Advanced Solid Tumors Read more
